

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**GI0010 US CNT1**

Applicants:  
**SLIJKHUIS, et al.**

Serial No.  
**10/084,814**

Filing Date:  
**February 2, 2002**

Title of Invention:  
**PROCESS FOR OXIDATION OF STEROIDS AND GENETICALLY ENGINEERED CELLS USED THEREIN**

<b>CERTIFICATE OF TRANSMISSION</b>	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, David J. Steadman, at 703-872-9306, on	
Date of Deposit	<u>April 19, 2004</u>
Printed Name of Person Signing Certificate	<u>Jonas Pierre, Sr.</u>
Signature	<u>[Signature]</u>

**Total Number of Pages Sent: 29**

Attorney: **F. Aaron Dubberley**

Reg. No. **41,001**

Group Art Unit: **1652**

Examiner: **STEADMAN, David J.**

**RECEIVED  
CENTRAL FAX CENTER**

TO: Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**OFFICIAL**

**APR 23 2004**

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal  |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____  |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>Response to Restriction Requirement and Amendment (Amendments to Abstract, Amendments to Specification, Remarks, and Substitute Specification)</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____  |
| <input type="checkbox"/> Maintenance Fee Transmittal           |   |

Receipt Confirmed:

Signed \_\_\_\_\_

Dated \_\_\_\_\_

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

APR. 19. 2004 4:21PM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

APR 23 2004

NO. 1748 P. 2  
**PATENT**

**OFFICIAL**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**SLJKHUIS, et al.**

Examiner: STEADMAN, David J.

Art Unit: 1652

Application No.: 10/084,814

Filed: February 2, 2002

Title: **PROCESS FOR OXIDATION OF  
STERIODS AND GENETICALLY  
ENGINEERED CELLS USED  
THEREIN**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

April 19, 2004

Date of transmission

Jonas Pierre, Sr.  
Signature

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Amendment and Provisional Election is in response to the Office Action of March 17, 2004. The Commissioner is authorized to charge any additional fees or credit any overpayment necessitated by this amendment to Deposit Account No. 18-1982.

Please amend the above-identified application as follows:

Amendments to the Abstract begin on page 2 of this paper.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.